sevelamer

Genzyme's sevelamer is the market share leader despite the fact that it has the highest pill burden.

A 22% reduction in death among patients who took non-calcium based treatments sevelamer and lanthanum.

Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin.

Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.

In the phosphate binder market, Genzyme's sevelamer compounds are being used to treat almost half of the dialysis patients.

A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium.

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.

Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.

Sevelamer, a drug indicated for prevention of hyperphosphataemia in patients with chronic renal failure, can significantly reduce serum uric acid.

Phosphate binders such as sevelamer may also be polymeric structures which bind to phosphate and are then excreted.

Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.

A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.

In people receiving hemodialysis, sevelamer can significantly reduce serum uric acid, apparently by adsorbing urate in the gut.

Diplomat will be the 2008 national Part D Assistance provider for Renagel(R) (sevelamer hydrochloride).

The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.

Others include drugs that reduce the production of uric acid: xanthine oxidase inhibitors, urate oxidase (rasburicase), and sevelamer.

Within the sevelamer franchise, patient conversion to Renvela stands at about 27% and about half of the Renvela patients had been switched from Renagel.

Among CKD patients, sevelamer and FMC's PhosLo each have approximately 36% market share.

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.

One may avoid these adverse effects by using phosphate binders that do not contain calcium or aluminium as active ingredients, such as lanthanum carbonate or sevelamer.

The products included: calcium carbonate, calcium acetate, sevelamer hydrochloride, aluminum hydroxide and Magnabind (magnesium and calcium).

Fosrenol had the strongest performance in France, however sevelamer (Renagel/Renvela) has a market share advantage over Fosrenol in every region.

Suki, W. N. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.

It was felt that Sevelamer, and the newer Calcimetics and Vitamin D analogues might be suitable areas for active and forceful Society representations.

Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.